Updates to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines

Effective for dates of service on and after **August 22, 2026**, the following updates will apply to Carelon Medical Benefits Management, Inc. Clinical Appropriateness Guidelines. As part of the Carelon guideline annual review process, these updates are focused on advancing efforts to drive clinically appropriate, safe, and affordable health care services.

Genetic Testing

Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance

- Added criteria for Signatera CDx, as it was FDA approved as a companion diagnostic for use with adjuvant immunotherapy in patients with muscle-invasive bladder cancer (MIBC)
- Removed Signatera, as this test is now FDA approved and considered medically necessary per above criteria.
- Removed test manufacturer names to align across Carelon guidelines.
- Added Cancerguard (not FDA-approved or cleared) as another MCED test example considered not medically necessary.
- Removed test manufacturer names to align across Carelon guidelines.